{"type":"trials","record":{"id":41924,"source_id":"clinicaltrials-gov","external_id":"NCT02387957","title":"A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)","brief_summary":"To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.","overall_status":"Terminated","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Ophthotech Corporation","enrollment":63,"countries":["United States"],"start_date":"2016-04-26","completion_date":"2017-01-01","last_update_date":"2024-10-30","source_url":"https://clinicaltrials.gov/study/NCT02387957","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Astellas Pharma Inc","interventions":["Fovista®","bevacizumab","ranibizumab","aflibercept"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Total Numer of Systemic Adverse Events — 2 years","Total Number of Other Adverse Events (>5%) — 2 years"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":true},"controlled_terms":["Age-Related Macular Degeneration","Fovista®","bevacizumab","ranibizumab","aflibercept"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct02387957","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2016-04-26 to 2017-01-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.892Z","intervention":["Fovista®","bevacizumab","ranibizumab","aflibercept"],"participants":63,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Total Numer of Systemic Adverse Events — 2 years","Total Number of Other Adverse Events (>5%) — 2 years"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41924","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}